Ratings Curaleaf Holdings, Inc. OTC Markets

Equities

CURLF

CA23126M1023

Market Closed - OTC Markets Other stock markets 03:59:17 2024-07-12 pm EDT			5-day change	1st Jan Change
4.213 ^USD	+0.79%		+10.00%	+3.77%

Jun. 24	Curaleaf Introduces Hemp-Derived THC Products Line, New Consumer E-Commerce Marketplace	MT
Jun. 24	Curaleaf Brief: Launching Hemp Derived Product Line and New Direct to Consumer Ecommerce Marketplace	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company has insufficient levels of profitability.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
CURALEAF HOLDINGS, INC.	+3.77%	3.12B		-
TRULIEVE CANNABIS CORP.	+99.71%	1.88B		C
VIREO GROWTH INC.	+90.48%	64.64M	-	-
SIMPLY BETTER BRANDS CORP.	+300.00%	58.35M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes